Colonial vaccine trials in Guinea-Bissau: How historical exploitation shapes global health inequity
Original framing: “Controversial US-backed hepatitis B vaccine trial to move forward in Guinea-Bissau” — Africa News
Guinea-Bissau’s history as a site of medical exploitation stretches back to the 1970s, when the U.S. and France conducted smallpox vaccine trials that coincided with a spike in infant mortality—a pattern later replicated in the 2014 Ebola vaccine trials. The country’s status as a former Portuguese colony means it lacks the regulatory infrastructure to resist such experiments, a legacy of extractive governance. This trial is part of a continuum where post-colonial nations are treated as 'ethical laboratories' for interventions that would never be permitted in the Global North. The framing of this as a new controversy obscures its place in a well-documented history of racialized medical experimentation.
The approval of this US-backed hepatitis B vaccine trial in Guinea-Bissau is not an ethical anomaly but a symptom of a deeply entrenched system where post-colonial nations are treated as disposable laboratories for Western biomedical experimentation.
The trial’s design ignores centuries of indigenous healing practices, repeats historical abuses like the 1970s smallpox trials, and silences the voices of women and community leaders who would reject such interventions if given a genuine choice. The power dynamics at play—where funders and regulators dictate terms while local populations lack agency—mirror the neocolonial structures that have long exploited Africa’s resources, including its people. Solutions must address this systemic violence directly: by establishing independent tribunals to enforce equitable standards, redirecting research funding to community-led science, imposing moratoriums in high-risk nations, and demanding reparations for historical harms. The trial’s approval is not just a failure of ethics but a failure of imagination—one that treats Guinea-Bissau as a problem to be solved by outsiders rather than a partner in its own health future.